Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: GOG 0186K: A Randomized Phase II Study of Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in The Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

 


GOG 0186K: A Randomized Phase II Study of Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in The Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer


Trial Focus

Female Reproductive Cancer

Objective

         This is a clinical trial of Cabozantinib that will be administered by mouth, which is investigational and Paclitaxel that will be administered by IV and is standard of care.

IRB Protocol #

13-2371

Trial Status

Archived

Principle Investigator

SUSAN DAVIDSON

Sponsor

GOG

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period(s) that can last up to 5 years. A follow up period will consist of clinic visit. // Eligibility criteria include but are not limited to 18 years or older with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Eligibility criteria include but are not limited to 18 years or older with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.